545,440 Shares in Prestige Consumer Healthcare Inc. (NYSE:PBH) Purchased by Raymond James Financial Inc.

Raymond James Financial Inc. purchased a new position in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 545,440 shares of the company's stock, valued at approximately $42,593,000. Raymond James Financial Inc. owned 1.10% of Prestige Consumer Healthcare as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also bought and sold shares of the company. Norges Bank bought a new position in Prestige Consumer Healthcare in the 4th quarter valued at about $40,009,000. Boston Trust Walden Corp boosted its position in shares of Prestige Consumer Healthcare by 43.5% during the 4th quarter. Boston Trust Walden Corp now owns 831,627 shares of the company's stock worth $64,942,000 after acquiring an additional 252,089 shares in the last quarter. Natixis Advisors LLC increased its stake in Prestige Consumer Healthcare by 1,335.1% in the fourth quarter. Natixis Advisors LLC now owns 209,246 shares of the company's stock valued at $16,340,000 after acquiring an additional 194,665 shares during the last quarter. JPMorgan Chase & Co. raised its position in Prestige Consumer Healthcare by 44.5% during the fourth quarter. JPMorgan Chase & Co. now owns 393,474 shares of the company's stock valued at $30,726,000 after purchasing an additional 121,219 shares in the last quarter. Finally, Wells Fargo & Company MN raised its position in Prestige Consumer Healthcare by 103.0% during the fourth quarter. Wells Fargo & Company MN now owns 199,449 shares of the company's stock valued at $15,575,000 after purchasing an additional 101,179 shares in the last quarter. Institutional investors and hedge funds own 99.95% of the company's stock.

Prestige Consumer Healthcare Trading Down 1.3 %

PBH traded down $1.03 during midday trading on Monday, hitting $79.25. 8,605 shares of the company were exchanged, compared to its average volume of 284,995. Prestige Consumer Healthcare Inc. has a 1-year low of $62.35 and a 1-year high of $90.04. The company has a quick ratio of 2.20, a current ratio of 3.68 and a debt-to-equity ratio of 0.56. The firm has a market capitalization of $3.93 billion, a P/E ratio of 18.58, a P/E/G ratio of 2.69 and a beta of 0.47. The firm's 50 day moving average price is $84.16 and its 200-day moving average price is $80.24.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its earnings results on Thursday, February 6th. The company reported $1.22 earnings per share for the quarter, beating analysts' consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. As a group, equities analysts forecast that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently commented on PBH. Canaccord Genuity Group boosted their price target on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a "buy" rating in a report on Friday, February 7th. StockNews.com cut shares of Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a report on Tuesday, April 8th. DA Davidson lifted their price target on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a "buy" rating in a report on Friday, February 7th. Royal Bank of Canada increased their price objective on shares of Prestige Consumer Healthcare from $96.00 to $97.00 and gave the company a "sector perform" rating in a research note on Friday, March 21st. Finally, Oppenheimer boosted their target price on shares of Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an "outperform" rating in a research note on Thursday, February 13th. Four analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to MarketBeat.com, Prestige Consumer Healthcare presently has a consensus rating of "Hold" and a consensus price target of $93.33.

Insiders Place Their Bets

In other news, SVP Mary Beth Fritz sold 1,678 shares of the firm's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $90.00, for a total transaction of $151,020.00. Following the completion of the sale, the senior vice president now owns 17,157 shares of the company's stock, valued at $1,544,130. This trade represents a 8.91 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Company insiders own 1.60% of the company's stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.